Companies
RemeGen
Next-gen biologics — High-efficacy payloads.
- Country
- China
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | RMB 5,850.2 million for the six months ended June 30, 2026 | quartr.com · hkexnews.hk |
| Capacity | 36,000L as of end of 2021; planned expansion to 80,000L before 2025 | hk-official.cmbi.info · pdf.dfcfw.com |
| Headcount | 3,146 employees as of June 30, 2026 | hkexnews.hk |
| Production site | Yantai, Shandong, China | hk-official.cmbi.info · pdf.dfcfw.com |
| Regulatory approval | Telitacicept (SLE, RA, gMG); Disitamab vedotin (GC, UC, advanced breast cancer) in China | ir.vorbio.com · remegen.com · www1.hkexnews.hk |
Independent sources: hk-official.cmbi.info · hkexnews.hk · ir.vorbio.com · pdf.dfcfw.com · quartr.com · www1.hkexnews.hk
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Antibody-drug conjugates (ADCs) | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.